Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryman HealthcareRHCGF +12.28%37 Days Sales Outstanding is 52.28 as of Mar. 2025, which is 84% below its 10-year median of 334.85. GuruFocus rates RHCGF with a GF Score™ of 37/100 and a GF Value™ of $3.97 (Significantly Undervalued). Among 664 Healthcare Providers & Services companies, Ryman Healthcare ranks worse than 91.72% on this metric.
The historical rank and industry rank for Ryman Healthcare's Days Sales Outstanding or its related term are showing as below:
RHCGF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 147.95 Med: 334.85 Max: 450.72
Current: 147.95
During the past 13 years, Ryman Healthcare's highest Days Sales Outstanding was 450.72. The lowest was 147.95. And the median was 334.85.
RHCGF's Days Sales Outstanding is ranked worse than 91.72% of 664
companies
in the Healthcare Providers & Services industry
Industry Median: 45.78
vs RHCGF: 147.95
Ryman Healthcare's Days Sales Outstanding
declined
from Mar. 2024 (363.88) to Mar. 2025 (52.28).
Ryman Healthcare (OTCPK:RHCGF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Ryman Healthcare Days Sales Outstanding Related Terms
Ryman Healthcare Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Ryman Healthcare's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RHCGF vs HCA, THC, DVA: Days Sales Outstanding Comparison
For the Medical Care Facilities subindustry, Ryman Healthcare's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryman Healthcare Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ryman Healthcare's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Ryman Healthcare's Days Sales Outstanding falls into.
Ryman Healthcare Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryman Healthcare (RHCGF) has a Days Sales Outstanding of 52.28 as of Mar. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ryman Healthcare and its competitors. This is 84% below median its historical median of 334.85. Over the past decade, Ryman Healthcare's Days Sales Outstanding has ranged from 147.95 to 450.72. According to the industry distribution chart, Ryman Healthcare ranks #609 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 91.7%.
Is Ryman Healthcare's Days Sales Outstanding too high?
Ryman Healthcare's current Days Sales Outstanding of 52.28 is 84% below median its 10-year median of 334.85. Over the past 10 years, this metric has ranged from a low of 147.95 to a high of 450.72. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.78. Ryman Healthcare's value of 52.28 is 14.2% above this industry median. Based on the distribution chart, Ryman Healthcare ranks #609 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Ryman Healthcare has a GF Score™ of 37/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ryman Healthcare's Days Sales Outstanding compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Ryman Healthcare ranks #609 out of 664 companies for Days Sales Outstanding. This places Ryman Healthcare in the lower half of its industry. The industry median Days Sales Outstanding is 45.78. Ryman Healthcare's value of 52.28 is 14.2% above this benchmark. Historically, Ryman Healthcare's own Days Sales Outstanding has ranged from 147.95 to 450.72 over the past decade. While the company's 10-year median is 334.85 vs. the industry median of 45.78, Ryman Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.78, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryman Healthcare's current Days Sales Outstanding of 52.28 is 14.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Ryman Healthcare and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryman Healthcare's current Days Sales Outstanding is 52.28, which is 84% below median its own 10-year median of 334.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryman Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Ryman Healthcare (RHCGF) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.97, compared to a current price of $1.11 — trading 72% below its estimated fair value. The current Days Sales Outstanding is 52.28, which is 84% below median its 10-year median of 334.85 and 14.2% above the Healthcare Providers & Services industry median of 45.78. Ryman Healthcare's overall GF Score™ is 37/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Ryman Healthcare (RHCGF), the current Days Sales Outstanding is 52.28 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryman Healthcare (RHCGF) Overvalued in 2026?
Based on GuruFocus' analysis, Ryman Healthcare stock appears to be undervalued.
The current stock price of $1.11 is trading 72% below its estimated GF Value™ of $3.97.
GuruFocus considers Ryman Healthcare to be Significantly Undervalued.
Key valuation signals for RHCGF:
Days Sales Outstanding: 52.28 (84% below median its 10-year median of 334.85)
GF Value™: $3.97 vs. price of $1.11 (72% below fair value)
Industry Position: 14.2% above the Healthcare Providers & Services median (#609 of 664)
No single metric tells the full story. See the RHCGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryman Healthcare Ltd is a retirement living and aged care provider operating in New Zealand and Australia. It owns and operates integrated retirement villages through its trading subsidiaries, which operate in the aged care and retirement living sector in New Zealand and Australia. The Group operates in a single industry: the provision of integrated retirement living and aged care for older people in New Zealand and Australia. The majority of revenue is derived from Care and village fees, which relate to the provision of accommodation, care and related services to aged care residents and retirement living residents.
37GF Score
Get the complete analysis for RHCGF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RHCGF has been successfully added to your 
